Engaging Thought Leadership
Over 80 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
Immuno 2025
12 - 14 March 2025 | London, UK
A three-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of immunotherapies.
Immuno 2025
.png?width=383&height=213&name=crescendo-logo%20(1).png)
Meet Our Expert Speakers
The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Immuno 2024: 25 - 26 April 2024, London, UK
Eleni Chantzoura
Director of Discovery,
MiNK Therapeutics
Mani Mudaliar
Target Analyst Director,
Exscientia
Miguel Gaspar
Director,
Astrazeneca
Sari Pesonen
Chief Scientific Officer,
Valo Therapeutics
Xi Zhao
Senior Principal Scientist,
AbbVie
Alastair Corbin
Principal Scientist,
Pathios Therapeutics
Alexandra Sevko
Director, Translational Research,
Prokarium
Amit Grover
Associate Principal Scientist,
AstraZeneca
Angelica Loskog
Chief Executive Officer,
Lokon Pharma AB
Benoit Van den Eynde
Professor,
Ludwig Institute for Cancer Research, Oxford University / VOLT
.jpg?length=600&name=acfa91cc-9563-4080-a43b-69834af66302-2-11764368speaker_photo-Christopher-Holland-1788-(3).jpg)
Chris Holland
Senior Manager,
Immunocore
Christine Rothe
Chief Development Officer,
iOmx Therapeutics
Cynthia Chauvin-Fleurence
Associate Principal Scientist,
AstraZeneca
Deepak Bhere
Assistant Professor,
University of South Carolina School of Medicine
Emiko DESVAUX
Principal Scientist, Translational Medicine,
Sanofi
Eric O'Neill
Professor of Cell & Molecular Biology,
Centre for Medicines Discovery
Gray Kueberuwa
Director of Pre-Clinical Safety Research,
Instil Bio
Ida Uddbäck
Senior Scientist,
Alligator Bioscience AB
Jens Vindahl Kringelum
Vice President,
Evaxion Biotech
Johan Pijnenborg
Chief Executive Officer,
GlycoTherapeutics B.V.
John Maher
Chief Scientific Officer,
Leucid Bio
.png?length=600&name=ea4e7755-5f7e-4ba0-a828-9ce9ab577c80-2-11764368speaker_photo-MicrosoftTeams-image-(1).png)
John Bridgeman
Research Director,
Instil Bio
Jon Moore
Chief Scientific Officer,
Epitopea Limited
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Kenneth Crook
Head of Translational Medicine,
Engimmune Therapeutics
Kieran Whelton
Data Scientist,
AbbVie
Klaus Okkenhaug
Professor of Immunology,
University of Cambridge
Livija Deban
Chief Scientific Officer,
Prokarium
Maria Amann
Principal Scientist,
China Innovation Center of Roche
María Laura Garcia Bermejo
Scientific Director,
Ramon y Cajal Health Research Institute (IRYCIS)
Maria Stella Sasso
Senior Principal Scientist,
Akamis Bio Ltd
.jpg?length=600&name=f154810c-d37d-4dd2-885b-5c0906b9208b-2-11764368speaker_photo-Mark-Cragg-(7.5).jpg)
Mark Cragg
Professor of Experimental Cancer Biology,
University of Southampton
Martin Miller
Senior Director,
AstraZeneca
Massimiliano Mellone
Senior Research,
AstraZeneca
Natalia Venetz
Senior Scientist,
Molecular Partners AG
Nisit Khandelwal
Founder and Former Chief Technology Officer,
iOmx Therapeutics
Øystein Rekdal
Chief Executive Officer,
Lytix Biopharma
Pedro Correa de Sampaio
Chief Executive Officer,
Neobe
Phil Brailey
SSII,
Crescendo Biologics
Philip Arlen
Chief Executive Officer,
Precision Biologics
Philip Beer
Chief Scientific Officer,
Step Pharma
Pierre Dönnes
Vice President,
Strike Pharma
Rahul Roychoudhuri
Professor,
University of Cambridge
Raj Mehta
Chief Executive Officer,
Adendra Therapeutics Ltd
Rick Kamps
NGS Lab Manager,
University of Maastricht Translational Genomics
Robyn Broad
Principal Scientist,
Adaptimmune
Russell LaMontagne
Chief Executive Officer,
Boston Immune Technologies and Therapeutics, Inc.
Sarah-Kim Friedrich-Becker
Senior Principal Scientist,
Abalos Therapeutics GmbH
Simon Barry
Executive Director,
AstraZeneca
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Steve Thorne
Cso,
Kalivir
Sylwia Marshall
Vice President Translational Sciences,
InvoX Pharma
Thorsten Ross
Vice President,
CatalYm GmbH
Timo Van den Berg
Senior Director Immuno-Oncology,
Byondis
William Jackson
Senior Scientist,
Bioarchitech Ltd
Yi-Ru Yu
Senior Scientist,
Pilatusbio
Yong-Jie Lu
Professor in Molecular Oncology,
Queen Mary University of London
Meet Our Esteemed Sponsors
Silver Sponsors
Bronze Sponsors
Network & Programme Sponsors
Sponsors of Immuno 2024 included
Antibody Analytics
Network & Programme Sponsor
Our mission is to unlock discoveries and develop solutions for biopharmaceutical companies seeking to overcome substantial scientific challenges by providing data of outstanding quality. Drawing on our immuno-oncology expertise, we have built up an array of assay systems to recreate immune cell interactions in the tumour microenvironment, intended to be as faithful to the physiological processes they are emulating as possible. With a strong focus on novel and emerging therapeutic classes that are designed to modulate these processes, our assay platforms are applicable to oncology, auto-immunity and beyond. At Antibody Analytics we believe that scientists deserve the best data, and patients deserve the best drugs. Led by a group of talented and engaged scientists, we look at biological problems in an openminded way to deliver beautifully designed, developed and qualified bioassays. We have developed a comprehensive portfolio of assays and platforms that can be tailored to support even the most complex of drug pipelines. Whether designing and developing bespoke bioassays or offering routine analysis on our already established assay platforms, Antibody Analytics has an exceptional track record of delivering beautiful results.
Batavia Biosciences
Bronze Sponsor
Batavia Biosciences is a science driven CDMO in all stages of process development and cGMP manufacturing for viral vaccines, viral vectors and recombinant proteins. We have ample experience in working with adeno-, AAV-, lenti-, gammaretro-, VSV-, measles-, and exotic viruses. Batavia Biosciences significantly contributes to ease human suffering from infectious diseases, cancer, and rare diseases by leveraging our innovative technologies and in-depth know-how. We do this for viral vaccines and cell and gene therapies at all stages of the development trajectory, from the transition into early clinical studies, to navigating late-stage clinical development and entering commercial manufacturing at higher speed, reduced costs, and with increased success. The company operates state-of-the-art development and manufacturing facilities in Europe and the US and, as part of the CJ CheilJedang global family, is building a strong position in global health with its strategic partners worldwide. Batavia Biosciences provides services for viral vector, viral vaccine and recombinant proteins from process development to cGMP manufacturing. The services include: - viral vector and protein expression vector construction - generation of viral vaccine seed stocks - mammalian cell line generation - transient protein production - upstream and downstream process optimization - medium development - scale-up development - assay development - product characterization - preclinical manufacturing - clinical manufacturing - commercial manufacturing
Biognosys AG
Bronze Sponsor
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
Canopy Biosciences- A Bruker Company
Silver Sponsor
Canopy Biosciences, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary technology ChipCytometry™ is a quantitative multiplex immunofluorescence imaging method for the spatial analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services™ with our CLIA-certified laboratory, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at CanopyBiosciences.com.
Cell Signalling Technology Europe B.V
Bronze Sponsor
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.
Charles River Laboratories, Inc.
Gold Sponsor
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Concept Life Sciences
Network & Programme Sponsor
Concept Life Sciences is a leading Contract Research Organization (CRO) specializing in chemistry, biology, ADME&DMPK, and toxicology services. Our focus spans key therapeutic areas, including neuroscience, oncology, immuno-oncology, and immunology. Committed to excellence, we offer tailored solutions to accelerate your research and drug development.
Crown Bioscience Inc
Gold Sponsor
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical and translational platforms to advance oncology and immuno-oncology treatment modalities.
ERBC Group
Network & Programme Sponsor
European Research Biological Center (ERBC) is a 50 years’ leading CRO committed to bridge the gap between preclinical and clinical research by better predicting the efficacy and safety of new compounds. Offering a comprehensive range of experimental capabilities, preclinical models, regulatory pre-IND package and consultancy services, ERBC allows biopharmaceutical and chemical industry professionals to de-risk innovation and enhance R&D productivity. With highly qualified teams in France and Italy, ERBC is offering a customer-centric approach while committed in improving all aspects of study design and conduct applying alternatives to animal testing as a priority.
Gempharmatech, Co.Ltd.
Silver Sponsor
GemPharmatech is a leading provider of genetically engineered mouse models (GEMMs) and services to global preclinical R&D communities. We specialize in developing animal models using cutting-edge gene-editing technologies with a large collection of KO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice. Our ultimate goal is to accelerate scientific advancement and pharmaceutical development by supporting our clients with the most innovative tools and services.
GenScript UK Ltd
Gold Sponsor
Genscript Biotech Corporation is a global biotech company. The Company’s mission is to “Make the Human and Nature Healthier through Biotechnology”. Genscript Biotech Corporation is a leading life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions.
.png?length=600&name=e21cf0e2-d3cd-4e01-8073-2b4c82598622-2-5668375logo-Hawk-(RGB-Full-Colour).png)
Hawk Biosystem
Network & Programme Sponsor
HAWK Biosystems are a deep-tech biotechnology company based in Spain who were spun out of the Francis Crick Institute and Cancer Research UK. HAWK have developed the platform technology, QF-Pro® ( Q uantifiable F unctional Pro teomics), which can spatially quantify protein-protein interactions and protein post-translational modifications at an unprecedented resolution and sensitivity, yielding deep insights into patient pathology samples, particularly in the domain of immuno-oncology.
HistologiX
Network & Programme Sponsor
HistologiX is a trusted GLP & GCP compliant CRO for tissue-based analysis - make the most of our expertise. We help you visualise and understand what your drug or device is doing to your key biomarkers at the cellular and tissue level. Working collaboratively, our experienced scientific team provides a bespoke service allowing you to make the most of our expertise in histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), In Situ Hybridisation (ISH) using RNAScope, whole slide digital scanning (bright-field and flourescent) & cutting-edge digital image analysis using Visiopharm and HALO. For each project, our experienced scientists work as an extension of your in-house team to define your bespoke project requirements and customise the study plan to ensure you get the results you need. Our scientific experts develop, optimise and validate biomarker assays for use in distribution, proof of concept, mechanism of action studies along with offering our bespoke regulatory tissue cross reactivity service. We provide an excellent quality technical service supporting biomarker evaluation of cutting-edge therapeutics including cell and gene therapies, oncolytic viruses, therapeutic antibodies, small molecules, and RNA modifying enzymes
Janvier Labs
Silver Sponsor
Janvier Group Biosciences is a key partner for biotech, pharma companies and research institutes. The overall mission of our group is to provide private and public researchers with a unique combination of models and translational services for studying human pathologies and evaluating drug candidates to improve human health. Thanks to the development of innovative in vitro, in vivo, and custom-created models, our researchers now have a wide range of tools that they can selectively choose to support the various validation stages of their research and development projects. In addition to models, and to reduce the significant attrition rate at the clinical stage, the Group has chosen to surround itself with top experts to develop particularly innovative and effective early evaluation and study services in therapeutic areas such as oncology, rare diseases, infectious diseases, metabolic diseases, or cardiovascular diseases. In these areas of expertise, the Group has enriched itself with the latest cutting-edge technologies to create and characterize new in vitro and in vivo models, evaluate efficacy and tolerance, identify targets, and elucidate the mechanisms of action of future therapeutic molecules. Thanks to the synergy of these predictive approaches, researchers now have early access to high-value models and services to offer the best chances of success to the preclinical and clinical development programs they conduct. Ultimately, patients will have easier access to new, effective, and reliable innovative therapies in the shortest possible timeframes.
Lunaphore Technologies, a Bio-Techne company
Bronze Sponsor
Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
.jpg?length=600&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
Nanion Technologies GmbH
Network & Programme Sponsor
Nanion Technologies is a global leading life sciences tools company combining since more than 20 years exceptional instrumentation with trusted scientific support, to accelerate successful drug development and scientific discoveries. As a leading provider of automated patch clamp systems with a wide range of throughput capabilities and formats, we have expanded our product range to in vitro systems for membrane pump/transporter, bilayer recordings, contractility and cell analytics measurements. From studying the biophysical properties and pharmacological profile of ion channels and transporters in native and reconstituted membranes to understanding the effect of their modulation on cell survival and function, our state-of-the-art instrumentation has revolutionized drug discovery, lead optimisation and safety assessment. Now, with our newest technology, AtlaZ, we introduce high-throughput impedance spectroscopy, allowing simultaneous, label-free and time resolved monitoring of diverse cellular responses. With the capability to track live cells in scalable throughput (6x 96-well plate configuration), AtlaZ operates across a range of frequencies (0.1 KHz – 100 KHz), unveiling nuanced information about cell confluence, proliferation and cytotoxicity, cancer immunotherapy as well as formation of tight junctions in epithelial and endothelial cell lines. Our user-oriented interface providing real-time and automated data analysis, offers simplicity you will love. Applications include: Cell Proliferation, Cytotoxicity, Immune Cell-Mediated Cytotoxicity, Cancer Immunotherapy, Immuno-Oncology, Oncolytic Viruses, Receptor-mediated Signalling.
Navinci
Silver Sponsor
Navinci is a Swedish biotech company specializing in developing innovative solutions for studying protein interactions. With a focus and a strong legacy in developing in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth.
Novigenix
Network & Programme Sponsor
Novigenix pioneers AI-driven healthcare solutions, analyzing RNA data to personalize cancer treatments and improve patient outcomes. Leveraging molecular technologies and AI, Novigenix maps immune system responses, facilitating tailored therapeutic advancements based on individual immune response profiles. For over a decade, Novigenix has demonstrated leadership in bringing precision immunology to the market, integrating multi-omics data with AI through its proprietary LITOSeek™ platform. This innovative approach offers insights into patient immune responses, driving precision therapy developments.
Proteome Sciences
Network & Programme Sponsor
Proteome Sciences is a CRO specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications. By using LC-MS2, SysQuant® and TMTcalibratorTM methodologies we can detect up to 8,000 of proteins/sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment. These key protein biomarkers can then be measured in a GCLP accredited Targeted Assay in a clinical trial, via a multiplexed assay of up to 100 proteins/sample. New! We now offer Single Cell Proteome analysis. New! We have just opened a full service lab in San Diego!
Q2 Solutions- ImmunXperts
Bronze Sponsor
ImmunXperts, a Q2 Solutions company operates a R&D laboratory located in Gosselies to serve clients worldwide, from biotechnology to pharmaceutical groups. The company’s specialty is to assess all aspects of the immune responses in donors and patients, supporting its partners in the full development cycle of novel drugs, biotherapeutics and cell and gene therapies. At ImmunXperts, you’ll find exceptional in vitro bioassay development services and support for early evaluation and screening of candidate therapeutics. Our highly experienced team will facilitate your research, from in silico immunogenicity assessment with epitope prediction to in vitro immunogenicity and immuno-functionality assays. We specialize in in vitro bioassays involving primary human immune cells and non-human primate cells. These tests are suitable for many areas of investigation, including immuno-oncology, inflammation, autoimmunity, cell and gene therapy, and prophylactic and therapeutic vaccines.
Reading Scientific Services Ltd
Network & Programme Sponsor
RSSL is the largest UK independent laboratory with over 300 scientists. From our fourth new 26,000 sq. ft facility, opened in Nov 2023, we provide the following key services to support Biotherapeutic companies and CDMO’s: • Cell potency bioassays (multiple end point) - dedicated culture suites for banking, transfection and bioassay • Flow cytometry • Specialist LC-MS services: viral vectors, proteins and mRNA therapeutics • Product characterisation to ICHQ6B • Safety testing • Method development & validation • Environmental monitoring • QP & GMP Training • GMP compliant labs for materials QC release testing and product investigations/contamination identification Available capacity for an immediate start
.jpg?length=600&name=a22319e4-81c8-48dc-9404-bbfd832a6ef7-2-5668375logo-Scailyte-white-(1).jpg)
Scailyte AG
Silver Sponsor
We are a leading biomarker and companion diagnostics company that solves the toughest clinical challenges by leveraging our unique AI-driven translational platform and single-cell multi-omics data. We have developed one of the first and most promising molecular diagnostics assays for diagnosing endometriosis and we are now focusing on deploying our approach in immunology and oncology - we are looking to partner with ambitious biotech and pharma companies and work together to bring precision medicine solutions to the patients.
SGS
Network & Programme Sponsor
SGS is the world’s leading inspection, verification, testing and certification company. With more than 90,000 employees, SGS operates a network of over 1,500 offices and laboratories around the world. The Life Science division serves pharmaceutical, biopharmaceutical, and medical device companies along the entire drug development pathway. With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products. SGS Vitrology provides a comprehensive range of biosafety services such as: virology, cell and molecular biology as well as microbiology and electron microscopy. Health Authorities, including the US FDA and the EMA, require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS Vitrology helps clients by ensuring product safety in satisfying these regulatory requirements. Our GLP/GMP facility is MHRA certified and US FDA audited.
Standard BioTools
Silver Sponsor
Standard BioTools™, previously known as Fluidigm, is driven by a bold vision – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop breakthroughs in human health faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Using Imaging Mass Cytometry™ to investigate the tumor and tissue microenvironment at subcellular resolution and assess cell phenotypes, signaling pathways and function enables translation of research findings into action. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com
Thermofisher Scientific
Silver Sponsor
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com
Volition
Network & Programme Sponsor
Volition is a leading epigenetics biomarker company, renowned for its proprietary liquid biopsy immunoassay approach to profiling nucleosomes. Nu.Q® Discover offers access to a range of assays targeting circulating nucleosomes in plasma as pharmacodynamic biomarkers of epigenetic inhibitors (targeting histone post-translational modifications (PTMs) and to monitor innate immune activation (NETosis) in inflammatory diseases and CAR-T cell therapy. The immunoassays provide non-invasive, quantitative insights, adding significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases. The assays are available on an automated chemiluminescence bead based platform as well as manual, ELISA plates and effectively correlate with disease progression and tumor burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes immunoassay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using mass spectrometry, and cell death/toxicity monitoring assays.
Scientists Develop First Mouse Model with Complete & Functional Human Immune System
The breakthrough in mouse models will allow researchers to study the human immune system in far greater detail at a far greater pace.
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
NHS Cancer Vaccine Launchpad to Give Thousands Access to Personalised Cancer Vaccines
NHS England aims to match up to 10,000 cancer patients to suitable personalised cancer vaccine clinical trials by 2030.
AI-Enabled Predictive Biomarker for Patient Response to Immunotherapy Using Easy-to-Measure Features
The predictive biomarker does not require multi-omic or screening data, but rather routine clinical features.
H5N1 Bird Flu Outbreaks: Effect on Vaccines
H5N1 outbreaks in the US have mobilised pandemic preparedness mechanisms with stockpiling of avian flu vaccines.
